How Bayer’s New Stroke Drug & Digital Push Boost Its Market Confidence
New FDA approval of Bayer’s Sunharbo boosts earnings outlook and offsets Xarelto decline, while debt cuts and data‑tech partnerships strengthen its pharma and crop science growth.
2 minutes to read









